Cardiovascular Risk
-
Tourmaline Bio Presents Phase 2 TRANQUILITY Trial Data at ESC 2025
Tourmaline Bio’s Phase 2 TRANQUILITY trial of pacibekitug demonstrated significant hs-CRP reductions in patients with elevated hs-CRP and chronic kidney disease. The 50mg quarterly dose achieved >85% hs-CRP reduction, a first for an IL-6 inhibitor. Statistically significant reductions were also observed in cardiovascular risk biomarkers like lipoprotein(a) and fibrinogen. These results support planned Phase 2 AAA study and Phase 3 ASCVD cardiovascular outcomes trial.
-
VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduces Hospitalizations & CVD Risk in High-Risk Patients: New REDUCE-IT® Analyses Presented at ESC 2025
Amarin Corporation presented REDUCE-IT® trial sub-analyses at ESC Congress 2025, highlighting the benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) regarding cardiovascular risk reduction. Key findings include a 9% drop in total hospitalizations and a 44% relative risk reduction in cardiovascular events for patients with Cardiovascular-Kidney-Metabolic (CKM) syndrome. The treatment also showed significant MACE reductions across all ApoB quartiles. The ESC/EAS guidelines reaffirmed icosapent ethyl as a Class IIA therapy.
